跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,803 条关于
“SEC61 inhibitors”
全部
13,803
临床试验
6,382
药物
3,224
机构
8
资讯
4,189
8个月前
Enodia Therapeutics Secures €20.7M Seed Funding to Advance Novel Protein Degradation Platform Targeting SEC61 Translocon
去年
Enodia Therapeutics Launches with Novel Protein Degradation Platform Targeting Cancer and Inflammatory Diseases
去年
Drug Hunter Highlights Key Pharmaceutical Patents and Clinical Updates from Late 2024
去年
Promising Therapeutic Advances for Rare Lymphomas: PI3K Inhibitors, EZH2 Inhibitors, and Immunotherapy Show Clinical Potential
5年前
CDK4/6 Inhibitors Show Potential in HR+/HER2- Early Breast Cancer Adjuvant Therapy
去年
Complement Inhibitors Show Promise in Diverse Clinical Trials
去年
NLRP3 Inhibitors Show Promise Across Autoimmune, Neurodegenerative, and Metabolic Diseases
12年前
Niraparib Maintenance Therapy Demonstrates Sustained Benefit in Recurrent Ovarian Cancer
4年前
PARP Inhibitors Show Promise in Ovarian Cancer Maintenance Therapy
2年前
NOX Inhibitors Show Promise in Fibrotic Diseases and Cancer Treatment
第 1 页,共 419 页
上一页
下一页